Drug Type Biological products |
Synonyms- |
Target |
Action modulators, inhibitors |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators), MerTK inhibitors(Tyrosine-protein kinase Mer inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 10 Dec 2022 | |
| Neoplasms | Preclinical | Germany | 10 Dec 2022 | |
| Neoplasms | Preclinical | Switzerland | 10 Dec 2022 |





